World Pharma News Digest - 28.08.2014
6 views
Skip to first unread message
Ruslan David
Aug 28, 2014, 10:16:06 AM8/28/14
to worldph...@googlegroups.com
Health IT Space Business Social Network (Europe)
Explore the beta version of the first business social networking platform for Health IT Professionals, named Health IT Space (Europe):
Read more...
http://www.healthitspace.eu
Fighting prostate cancer with a tomato-rich diet
Men who eat over 10 portions a week of tomatoes have an 18 per cent lower risk of developing prostate cancer, new research suggests. With 35,000 new cases every year in the UK, and around 10,000 deaths, prostate cancer is the second most common cancer in men worldwide. Rates are higher in developed countries, which some experts believe is linked to a Westernised diet and lifestyle.
Read more...
http://www.worldpharmanews.com/research/2871-fighting-prostate-cancer-with-a-tomato-rich-diet
Aspirin cuts risk of clots, DVT by a third
Low dose aspirin lowers the occurrence of new venous blood clots - and represents a reasonable treatment option for patients who are not candidates for long-term anticoagulant drugs, such as warfarin, according to a new study published in current issue of Circulation.
Read more...
http://www.worldpharmanews.com/research/2870-aspirin-cuts-risk-of-clots-dvt-by-a-third
Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen
Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's crizotinib (XALKORI®) with Merck's investigational anti-PD-1 antibody pembrolizumab,
Read more...
http://www.worldpharmanews.com/pfizer/2869-pfizer-and-merck-to-collaborate-on-study-evaluating-novel-anti-cancer-combination-regimen
Roche and InterMune reach definitive merger agreement
Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 8.3 billion on a fully diluted basis.
Read more...
http://www.worldpharmanews.com/roche/2868-roche-and-intermune-reach-definitive-merger-agreement
Insulin offers new hope for the treatment of acute pancreatitis
Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting and systemic inflammation. Every year in the UK around 20,000 patients are diagnosed with the disease resulting in 1000 deaths. There is no immediate cure and treatment is restricted to intravenous fluid and nutritional support.
Read more...
http://www.worldpharmanews.com/research/2867-insulin-offers-new-hope-for-the-treatment-of-acute-pancreatitis
Experts denounce clinical trials of unscientific, 'alternative' medicines
Experts writing in the Cell Press journal Trends in Molecular Medicine on August 20th call for an end to clinical trials of "highly implausible treatments" such as homeopathy and reiki. Over the last two decades, such complementary and alternative medicine (CAM) treatments have been embraced in medical academia despite budget constraints and the fact that they rest on dubious science, they say.
Read more...
http://www.worldpharmanews.com/research/2866-experts-denounce-clinical-trials-of-unscientific-alternative-medicines
Novartis provides drug candidate compounds to TB Alliance
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).
Read more...
http://www.worldpharmanews.com/novartis/2865-novartis-provides-drug-candidate-compounds-to-tb-alliance
United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor). The government is not planning any further action.
Read more...
http://www.worldpharmanews.com/astrazeneca/2864-united-states-department-of-justice-closes-investigation-into-plato-clinical-trial-for-brilinta
Aspirin has a second effect
Hugely popular non-steroidal anti-inflammation drugs like aspirin, naproxen and ibuprofen all work by inhibiting or killing an enzyme called cyclooxygenase - a key catalyst in production of hormone-like lipid compounds called prostaglandins that are linked to a variety of ailments, from headaches and arthritis to menstrual cramps and wound sepsis.
Read more...
http://www.worldpharmanews.com/research/2863-aspirin-has-a-second-effect
FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.(1)
Read more...
http://www.worldpharmanews.com/roche/2862-fda-approves-roches-avastin-plus-chemotherapy-for-treatment-of-advanced-cervical-cancer
Aspirin may slow recurrence in breast cancer patients
New findings published in the journal Cancer Research reveal that some postmenopausal overweight breast cancer patients who use common anti-inflammatory drugs like aspirin or ibuprofen have significantly lower breast cancer recurrence rates. Researchers from the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio and the University of Texas at Austin began by examining blood serum from CTRC breast cancer patients, said CTRC oncologist Andrew Brenner, M.D., Ph.D.
Read more...
http://www.worldpharmanews.com/research/2861-aspirin-may-slow-recurrence-in-breast-cancer-patients
FDA warns consumers about fraudulent Ebola treatment products
The U.S. Food and Drug Administration is advising consumers to be aware of products sold online claiming to prevent or treat the Ebola virus. Since the outbreak of the Ebola virus in West Africa, the FDA has seen and received consumer complaints about a variety of products claiming to either prevent the Ebola virus or treat the infection.
Read more...
http://www.worldpharmanews.com/fda/2860-fda-warns-consumers-about-fraudulent-ebola-treatment-products
Cell discovery brings blood disorder cure closer
A cure for a range of blood disorders and immune diseases is in sight, according to scientists who have unravelled the mystery of stem cell generation. The Australian study, led by researchers at the Australian Regenerative Medicine Institute (ARMI) at Monash University and the Garvan Institute of Medical Research, is published in Nature. It identifies for the first time mechanisms in the body that trigger hematopoietic stem cell (HSC) production.
Read more...
http://www.worldpharmanews.com/research/2859-cell-discovery-brings-blood-disorder-cure-closer
Sanofi and MannKind announce global licensing agreement for Afrezza® (insulin human) rapid-acting inhaled insulin
Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
Read more...
http://www.worldpharmanews.com/sanofi/2858-sanofi-and-mannkind-announce-global-licensing-agreement-for-afrezzar-insulin-human-rapid-acting-inhaled-insulin
Bone drugs may not protect osteoporotic women from breast cancer
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF). The drugs' protective effect was widely assumed after several observational studies showed that women who took them were less likely to get breast cancer.
Read more...
http://www.worldpharmanews.com/research/2857-bone-drugs-may-not-protect-osteoporotic-women-from-breast-cancer
Newly discovered heart molecule could lead to effective treatment for heart failure
Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating, and preventing, heart failure. The newly discovered molecule provides the heart with a tool to block a protein that orchestrates genetic disruptions when the heart is subjected to stress, such as high blood pressure.
Read more...
http://www.worldpharmanews.com/research/2856-newly-discovered-heart-molecule-could-lead-to-effective-treatment-for-heart-failure
Study shows type 2 diabetics can live longer than people without the disease
Patients treated with a drug widely prescribed for type 2 diabetes can live longer than people without the condition, a large-scale study involving over 180,000 people has shown. The findings indicate that a drug known as metformin, used to control glucose levels in the body and already known to exhibit anticancer properties, could offer prognostic and prophylactic benefits to people without diabetes.
Read more...
http://www.worldpharmanews.com/research/2855-study-shows-type-2-diabetics-can-live-longer-than-people-without-the-disease
In search for Alzheimer's drug
Researchers at Yale School of Medicine have discovered a new drug compound that reverses the brain deficits of Alzheimer's disease in an animal model. Their findings are published in the Aug. 5 issue of the journal PLoS Biology. The compound, TC-2153, inhibits the negative effects of a protein called STtriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory.
Read more...
http://www.worldpharmanews.com/research/2854-in-search-for-alzheimers-drug
Allied Minds and Bristol-Myers Squibb form new enterprise
Bristol-Myers SquibbAllied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY) have announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.
Read more...
http://www.worldpharmanews.com/bms/2853-allied-minds-and-bristol-myers-squibb-form-new-enterprise
Aspirin: Scientists believe cancer prevention benefits outweigh harms
New research from Queen Mary University of London (QMUL) reveals taking aspirin can significantly reduce the risk of developing - and dying from - the major cancers of the digestive tract, i.e. bowel, stomach and oesophageal cancer. For the first time, scientists have reviewed all the available evidence from many studies and clinical trials assessing both the benefits and harms of preventive use of aspirin.
Read more...
http://www.worldpharmanews.com/research/2852-aspirin-scientists-believe-cancer-prevention-benefits-outweigh-harms
PharmaNews.eu / Latest News
Fighting prostate cancer with a tomato-rich diet
http://www.pharmanews.eu/research-and-development/1471-fighting-prostate-cancer-with-a-tomato-rich-diet
A novel pathway for prevention of heart attack and stroke
http://www.pharmanews.eu/research-and-development/1470-a-novel-pathway-for-prevention-of-heart-attack-and-stroke
UCB expands access to clinical study data
http://www.pharmanews.eu/ucb/1469-ucb-expands-access-to-clinical-study-data
Europe to boost cooperation with international partners on generics
http://www.pharmanews.eu/ema/1468-europe-to-boost-cooperation-with-international-partners-on-generics
Community pharmacies could play bigger part in tackling poor health
http://www.pharmanews.eu/research-and-development/1467-community-pharmacies-could-play-bigger-part-in-tackling-poor-health
Aspirin: Scientists believe cancer prevention benefits outweigh harms
http://www.pharmanews.eu/research-and-development/1466-aspirin-scientists-believe-cancer-prevention-benefits-outweigh-harms
Potential basis for the treatment and prevention of Parkinson's disease
http://www.pharmanews.eu/research-and-development/1465-potential-basis-for-the-treatment-and-prevention-of-parkinsons-disease
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
Health IT Space, http://www.healthitspace.eu
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Explore the beta version of the first business social networking platform for Health IT Professionals, named Health IT Space (Europe):
Read more...
http://www.healthitspace.eu
Fighting prostate cancer with a tomato-rich diet
Men who eat over 10 portions a week of tomatoes have an 18 per cent lower risk of developing prostate cancer, new research suggests. With 35,000 new cases every year in the UK, and around 10,000 deaths, prostate cancer is the second most common cancer in men worldwide. Rates are higher in developed countries, which some experts believe is linked to a Westernised diet and lifestyle.
Read more...
http://www.worldpharmanews.com/research/2871-fighting-prostate-cancer-with-a-tomato-rich-diet
Aspirin cuts risk of clots, DVT by a third
Low dose aspirin lowers the occurrence of new venous blood clots - and represents a reasonable treatment option for patients who are not candidates for long-term anticoagulant drugs, such as warfarin, according to a new study published in current issue of Circulation.
Read more...
http://www.worldpharmanews.com/research/2870-aspirin-cuts-risk-of-clots-dvt-by-a-third
Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen
Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's crizotinib (XALKORI®) with Merck's investigational anti-PD-1 antibody pembrolizumab,
Read more...
http://www.worldpharmanews.com/pfizer/2869-pfizer-and-merck-to-collaborate-on-study-evaluating-novel-anti-cancer-combination-regimen
Roche and InterMune reach definitive merger agreement
Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 8.3 billion on a fully diluted basis.
Read more...
http://www.worldpharmanews.com/roche/2868-roche-and-intermune-reach-definitive-merger-agreement
Insulin offers new hope for the treatment of acute pancreatitis
Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting and systemic inflammation. Every year in the UK around 20,000 patients are diagnosed with the disease resulting in 1000 deaths. There is no immediate cure and treatment is restricted to intravenous fluid and nutritional support.
Read more...
http://www.worldpharmanews.com/research/2867-insulin-offers-new-hope-for-the-treatment-of-acute-pancreatitis
Experts denounce clinical trials of unscientific, 'alternative' medicines
Experts writing in the Cell Press journal Trends in Molecular Medicine on August 20th call for an end to clinical trials of "highly implausible treatments" such as homeopathy and reiki. Over the last two decades, such complementary and alternative medicine (CAM) treatments have been embraced in medical academia despite budget constraints and the fact that they rest on dubious science, they say.
Read more...
http://www.worldpharmanews.com/research/2866-experts-denounce-clinical-trials-of-unscientific-alternative-medicines
Novartis provides drug candidate compounds to TB Alliance
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).
Read more...
http://www.worldpharmanews.com/novartis/2865-novartis-provides-drug-candidate-compounds-to-tb-alliance
United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor). The government is not planning any further action.
Read more...
http://www.worldpharmanews.com/astrazeneca/2864-united-states-department-of-justice-closes-investigation-into-plato-clinical-trial-for-brilinta
Aspirin has a second effect
Hugely popular non-steroidal anti-inflammation drugs like aspirin, naproxen and ibuprofen all work by inhibiting or killing an enzyme called cyclooxygenase - a key catalyst in production of hormone-like lipid compounds called prostaglandins that are linked to a variety of ailments, from headaches and arthritis to menstrual cramps and wound sepsis.
Read more...
http://www.worldpharmanews.com/research/2863-aspirin-has-a-second-effect
FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.(1)
Read more...
http://www.worldpharmanews.com/roche/2862-fda-approves-roches-avastin-plus-chemotherapy-for-treatment-of-advanced-cervical-cancer
Aspirin may slow recurrence in breast cancer patients
New findings published in the journal Cancer Research reveal that some postmenopausal overweight breast cancer patients who use common anti-inflammatory drugs like aspirin or ibuprofen have significantly lower breast cancer recurrence rates. Researchers from the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio and the University of Texas at Austin began by examining blood serum from CTRC breast cancer patients, said CTRC oncologist Andrew Brenner, M.D., Ph.D.
Read more...
http://www.worldpharmanews.com/research/2861-aspirin-may-slow-recurrence-in-breast-cancer-patients
FDA warns consumers about fraudulent Ebola treatment products
The U.S. Food and Drug Administration is advising consumers to be aware of products sold online claiming to prevent or treat the Ebola virus. Since the outbreak of the Ebola virus in West Africa, the FDA has seen and received consumer complaints about a variety of products claiming to either prevent the Ebola virus or treat the infection.
Read more...
http://www.worldpharmanews.com/fda/2860-fda-warns-consumers-about-fraudulent-ebola-treatment-products
Cell discovery brings blood disorder cure closer
A cure for a range of blood disorders and immune diseases is in sight, according to scientists who have unravelled the mystery of stem cell generation. The Australian study, led by researchers at the Australian Regenerative Medicine Institute (ARMI) at Monash University and the Garvan Institute of Medical Research, is published in Nature. It identifies for the first time mechanisms in the body that trigger hematopoietic stem cell (HSC) production.
Read more...
http://www.worldpharmanews.com/research/2859-cell-discovery-brings-blood-disorder-cure-closer
Sanofi and MannKind announce global licensing agreement for Afrezza® (insulin human) rapid-acting inhaled insulin
Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
Read more...
http://www.worldpharmanews.com/sanofi/2858-sanofi-and-mannkind-announce-global-licensing-agreement-for-afrezzar-insulin-human-rapid-acting-inhaled-insulin
Bone drugs may not protect osteoporotic women from breast cancer
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF). The drugs' protective effect was widely assumed after several observational studies showed that women who took them were less likely to get breast cancer.
Read more...
http://www.worldpharmanews.com/research/2857-bone-drugs-may-not-protect-osteoporotic-women-from-breast-cancer
Newly discovered heart molecule could lead to effective treatment for heart failure
Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating, and preventing, heart failure. The newly discovered molecule provides the heart with a tool to block a protein that orchestrates genetic disruptions when the heart is subjected to stress, such as high blood pressure.
Read more...
http://www.worldpharmanews.com/research/2856-newly-discovered-heart-molecule-could-lead-to-effective-treatment-for-heart-failure
Study shows type 2 diabetics can live longer than people without the disease
Patients treated with a drug widely prescribed for type 2 diabetes can live longer than people without the condition, a large-scale study involving over 180,000 people has shown. The findings indicate that a drug known as metformin, used to control glucose levels in the body and already known to exhibit anticancer properties, could offer prognostic and prophylactic benefits to people without diabetes.
Read more...
http://www.worldpharmanews.com/research/2855-study-shows-type-2-diabetics-can-live-longer-than-people-without-the-disease
In search for Alzheimer's drug
Researchers at Yale School of Medicine have discovered a new drug compound that reverses the brain deficits of Alzheimer's disease in an animal model. Their findings are published in the Aug. 5 issue of the journal PLoS Biology. The compound, TC-2153, inhibits the negative effects of a protein called STtriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory.
Read more...
http://www.worldpharmanews.com/research/2854-in-search-for-alzheimers-drug
Allied Minds and Bristol-Myers Squibb form new enterprise
Bristol-Myers SquibbAllied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY) have announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.
Read more...
http://www.worldpharmanews.com/bms/2853-allied-minds-and-bristol-myers-squibb-form-new-enterprise
Aspirin: Scientists believe cancer prevention benefits outweigh harms
New research from Queen Mary University of London (QMUL) reveals taking aspirin can significantly reduce the risk of developing - and dying from - the major cancers of the digestive tract, i.e. bowel, stomach and oesophageal cancer. For the first time, scientists have reviewed all the available evidence from many studies and clinical trials assessing both the benefits and harms of preventive use of aspirin.
Read more...
http://www.worldpharmanews.com/research/2852-aspirin-scientists-believe-cancer-prevention-benefits-outweigh-harms
PharmaNews.eu / Latest News
Fighting prostate cancer with a tomato-rich diet
http://www.pharmanews.eu/research-and-development/1471-fighting-prostate-cancer-with-a-tomato-rich-diet
A novel pathway for prevention of heart attack and stroke
http://www.pharmanews.eu/research-and-development/1470-a-novel-pathway-for-prevention-of-heart-attack-and-stroke
UCB expands access to clinical study data
http://www.pharmanews.eu/ucb/1469-ucb-expands-access-to-clinical-study-data
Europe to boost cooperation with international partners on generics
http://www.pharmanews.eu/ema/1468-europe-to-boost-cooperation-with-international-partners-on-generics
Community pharmacies could play bigger part in tackling poor health
http://www.pharmanews.eu/research-and-development/1467-community-pharmacies-could-play-bigger-part-in-tackling-poor-health
Aspirin: Scientists believe cancer prevention benefits outweigh harms
http://www.pharmanews.eu/research-and-development/1466-aspirin-scientists-believe-cancer-prevention-benefits-outweigh-harms
Potential basis for the treatment and prevention of Parkinson's disease
http://www.pharmanews.eu/research-and-development/1465-potential-basis-for-the-treatment-and-prevention-of-parkinsons-disease
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
Health IT Space, http://www.healthitspace.eu
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages